Buying and holding forever sets a high bar. It means looking past the next result and focusing on businesses that have the potential to keep getting larger, stronger, and more valuable over many years.
That does not mean share prices will rise in a straight line. They never do. But the right companies can use time to their advantage.
Here are three amazing ASX growth shares that could fit that mould.
Lovisa Holdings Ltd (ASX: LOV)
Lovisa has turned a simple retail concept into a global rollout story.
The company sells affordable fashion jewellery through a store model that can be replicated across many markets.
Its appeal is the combination of global store growth and disciplined retailing. The business has already shown that its model can travel, and there are still large markets where its presence remains relatively small.
Fashion retail is not without risk. Consumer spending can soften and trends can shift. But Lovisa has a track record of moving quickly, keeping its ranges fresh, and maintaining a clear customer proposition.
If management continues to execute on its international expansion, this could be an ASX share with a very long runway for growth.
Pro Medicus Ltd (ASX: PME)
Pro Medicus is one of the rare ASX technology companies that has built a world-class niche.
Its Visage platform helps hospitals manage and view medical images with speed and efficiency. That matters because medical imaging is becoming more data-heavy, while health systems are under pressure to improve productivity.
This ASX growth share is solving a real problem. Radiologists, who are in short supply, are dealing with larger scan files, rising workloads, and growing demand for faster results. Visage helps address this by making imaging workflows more efficient.
Pro Medicus has built a strong position in the United States, where major hospital networks can sign long-term contracts and expand usage over time. Once embedded, the software becomes a critical part of clinical operations.
Its valuation is often demanding, but the business quality is hard to ignore. With healthcare data volumes continuing to grow, Pro Medicus arguably remains one of the ASX's most compelling long-term growth stories.
Xero Ltd (ASX: XRO)
Xero is building around one of the most important workflows for small businesses: money.
Its cloud platform helps businesses manage accounting, payroll, invoicing, payments, and financial information. Once a business is running on Xero, the software can become deeply embedded in daily operations.
That creates a powerful base for long-term growth. Xero can add more customers, expand in larger markets, and increase the value of each subscriber by adding new services.
The company's opportunity in the United States remains particularly important. It is a large market, and Xero's position there is still much smaller than in Australia, New Zealand, and the UK.
The good news is that recent updates show that Xero is gaining traction there. If it can build on this, then the future could be very bright for this ASX growth share.
The post 3 amazing ASX growth shares to buy and hold forever appeared first on The Motley Fool Australia.
Motley Fool contributor James Mickleboro has positions in Lovisa, Pro Medicus, and Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Lovisa and Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool Australia has recommended Lovisa and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026